Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
نویسندگان
چکیده
منابع مشابه
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes
Alzheimer disease (AD) drug development has a high failure rate. Drug development decision making can be improved based on lessons learned from past trials. Improved interpretation of animal models, better pharmacologic characterization in phase I and phase II trials, appropriate sample size, diagnosis of AD with biomarker support, optimization of global recruitment, and avoiding inappropriate ...
متن کاملLessons learned from radiation oncology clinical trials.
A workshop entitled "Lessons Learned from Radiation Oncology Trials" was held on December 7-8, 2011, in Bethesda, MD, to present and discuss some of the recently conducted radiation oncology clinical trials with a focus on those that failed to refute the null hypothesis. The objectives of this workshop were to summarize and examine the questions that these trials provoked, to assess the quality...
متن کاملClinical trials in systemic sclerosis: lessons learned and outcomes
The pathogenesis of systemic sclerosis (SSc) is complex and largely unclear. The clinical heterogeneity of the disease and its progression over a number of years makes the choice of endpoints in the design of clinical trials difficult. The overwhelming need in this disease is to diagnose it early and identify those patients who will benefit most from early, aggressive treatment that potentially...
متن کاملClinical Trials and Novel Pathogens: Lessons Learned from SARS
During the recent global outbreak of severe acute respiratory syndrome (SARS), thousands of patients received treatments of uncertain efficacy and known toxicity such as ribavirin and corticosteroids. Despite this, no controlled clinical trials assessing the efficacy of these agents were conducted. If a second global SARS outbreak occurred, clinicians would not have controlled data on which to ...
متن کاملLessons learned from recent randomized clinical trials for intermittent claudication.
It is well recognized that lower extremity peripheral arterial disease (PAD) is highly prevalent and results in significant cardiovascular mortality akin to cardiovascular disease.1 Among patients with PAD there is a broad range of clinical manifestations, with a third of patients having typical intermittent claudication (IC). The symptoms of lower extremity PAD, even in a stable nonlimb threat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Translational Science
سال: 2017
ISSN: 1752-8054
DOI: 10.1111/cts.12491